FirstWord Pharma PLUS editors Michael Flanagan, Virginia Li and Simon King discuss whether a spate of deals this week is evidence of an eventful year ahead for bio-pharma M&A, take a closer look at Pfizer’s acquisition of Arena Pharmaceuticals and highlight some of the standout moments from the recent ASH conference.